Neurological & Psychological Disorders
News on research and diagnostic developments in neuroscience.
BioArctic Doses First Parkinson's Patient in Trial of Alpha-Synuclein-Targeting Drug
Exidavnemab is a monoclonal antibody designed to eliminate aggregated clumps of the protein biomarker and slow progression of Parkinson's disease.
Denali Therapeutics Doses First LRRK2 Parkinson's Patient in Phase IIa Trial
BIIB122, previously known as DNL151, is a small molecule designed to inhibit LRRK2, mutations in which are the most common cause of inherited Parkinson's.
Gain Therapeutics to Start Testing GCase-Targeted Drug in Patients with GBA1, Sporadic Parkinson's
Premium
The company is hoping to show GT-02287 can slow Parkinson's progression by restoring function of GCase, an enzyme encoded by GBA1.
GeneDx Launches Program to Boost Access to Exome Testing for Pediatric Epilepsy Patients
In partnership with Biogen, Praxis Precision Medicines, and Stoke Therapeutics, the program will also contribute to GeneDx's rare disease database.
Novartis Pens $2.9B Deal With PTC Therapeutics for Huntington's Disease Drug
Novartis licensed PTC's PTC518 Huntington's disease program and related molecules and will pay $1 billion upfront as well as other costs.